Kickstart your career by applying for...
Institute vows to roll back growth...
Oh, the places you'll go with...
This first in a series of...
The conflict between genetic diagnostic test makers eager to recoup development costs through patent protection and patient groups seeking broader access to the tests resurfaced during the first of two hearings required by the patent law overhaul enacted in September. The hearing was held by the U.S. Patent and Trademark Office (USPTO) and is required to study how to ensure availability of confirming genetic diagnostic tests where gene patents and exclusive licensing for such tests exist. The final report is due June 16. Industry advocates oppose government efforts to force them to ensure independent second opinion genetic diagnostic testing, calling that an unlawful infringement of their patents. Patient advocates oppose the patenting of genes and genetic diagnostic tests, saying the resulting patent monopolies harm patients.
Unable to get Jobs Listings.
Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?
Be sure to add firstname.lastname@example.org
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2014 Genetic Engineering & Biotechnology News All Rights Reserved